Following its Q3 report, shares of telemedicine and virtual healthcare company Teladoc (NYSE:TDOC) hit a 52-week low in Thursday’s trading. They dropped as low as 7% as investors took the sidelines in the wake of the disappointing report. The firm reported weaker-than-expected Q3 earnings and posted a lower financial forecast, with plans to conduct an operational review of its business.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Beyond the Q3 miss, the company reported an 8% increase in revenue to $660 million but missed estimates by $4M. In addition, it noted that its Chronic Management business and membership growth drove the rise in revenue.
Furthermore, income from Access Fees increased by 8% to $582 million, while income from Other Sources increased by 10% to $78 million. International revenue increased 17% to $91 million, while U.S. sales increased 7% to $569 million.
What is the Future of TDOC?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on TDOC stock based on two Buys, five Holds, and one Sell assigned in the past three months, as indicated by the graphic above. Furthermore, the average TDOC price target of $23.86 per share implies a 48.01% upside potential.
